查看購物車
  • Simplified Chinese
  • English
  • Japanese
北美基因分型市場預測至 2031 年 - 區域分析 - 按產品類型、技術、應用和最終用戶
市場調查報告書
商品編碼
1666233

北美基因分型市場預測至 2031 年 - 區域分析 - 按產品類型、技術、應用和最終用戶

North America Genotyping Market Forecast to 2031 - Regional Analysis - by Product Type, Technology, Application, and End user
出版日期: | 出版商: The Insight Partners | 英文 147 Pages | 訂單完成後即時交付

價格

2023 年北美基因分型市值為 120.4457 億美元，預計到 2031 年將達到 629.0063 億美元；預計 2023 年至 2031 年的複合年成長率為 23.0%。

遺傳疾病和罕見疾病診斷應用推動北美基因分型市場發展

根據世界衛生組織 (WHO) 的數據，2050 年可能會出現約 3,500 萬例新發癌症病例，比 2022 年的 2,000 萬例增加 77%。這種疾病影響了超過600萬各個年齡層的美國人。根據該協會的估計，截至 2022 年，650 萬 65 歲以上的美國人患有阿茲海默症，其中 73% 年齡在 75 歲以上。根據《健康監測雜誌》發表的一項研究，全球有多達 3 億人患有罕見疾病。儘管單一疾病很罕見，但它們共同為全球醫療保健系統帶來了重大挑戰。

由於癌症、阿茲海默症和罕見疾病在臨床上難以識別，基因分型成為族群診斷檢測的支柱。可以將從基因分型獲得的 DNA 序列與樣本或參考序列進行比較以確定變異。基因分型也用於檢測單核苷酸多態性（SNP），即群體內遺傳互補的微小變異。人類基因組擁有近6.6億個SNP，這是最常見的遺傳變異。此外，透過比較健康和患病人群的多態性，全基因組關聯研究 (GWAS) 可以揭示常見疾病與 SNP 之間的關聯。 GWAS 可以透過尋找可能的原因來解開潛在疾病狀態的分子機制。 SNP 甚至存在於單細胞生物中，例如細菌。 SNP 基因分型可以區分微生物分離株，甚至可以用於識別抗生素抗藥性菌株。基於SNP的菌株檢測對各個藥物和臨床分析都有重大的影響，在傳染病流行病學中也得到了應用。

北美基因分型市場概覽

北美基因分型市場分為美國、加拿大和墨西哥。擴大採用技術先進的產品和解決方案以及不斷湧現的研究和開發活動是該地區基因分型市場受益的因素。此外，政府主導的計畫（例如「我們所有人的研究計畫」）、各個基因組學界發起的計劃以及人們對基因分型服務的日益認知是推動北美市場擴張的主要驅動力。

北美基因分型市場收入及預測（百萬美元）

北美基因分型市場細分

北美基因分型市場分為產品類型、技術、應用、最終用戶和國家。

根據產品類型，北美基因分型市場分為儀器、試劑和試劑盒、生物資訊學和基因分型服務。試劑和試劑盒部分在 2023 年佔據了最大的市場佔有率。

根據技術，北美基因分型市場分為微陣列、毛細管電泳、定序、聚合酶鍊式反應（PCR）、基質輔助雷射解吸/MALDI-TOF 和其他技術。聚合酶鏈反應 (PCR) 領域在 2023 年佔據了最大的市場佔有率。

根據應用，北美基因分型市場細分為藥物基因組學、診斷和個人化醫療、動物遺傳學、農業生物技術和其他應用。 2023 年，診斷和個人化醫療領域佔據最大的市場佔有率。

就最終用戶而言，北美基因分型市場分為製藥和生物製藥公司、診斷和研究實驗室、學術機構和其他最終用戶。 2023 年，製藥和生物製藥公司部門佔據了最大的市場佔有率。

依國家分類，北美基因分型市場分為美國、加拿大和墨西哥。 2023 年美國佔據北美基因分型市場的主導佔有率。

Hoffmann-La Roche Ltd、QIAGEN NV、Merck KGaA、Thermo Fisher Scientific Inc、BioTek Instruments, Inc、TRIMGEN CORPORATION、Illumina Inc、Danaher Corp、Bio-Rad Laboratories Inc、GE HealthCare Technologies Inc、Standard BioTools Inc、Laboratory Corp of America、Sooratory Corp.是北美基因分型市場的一些領導公司。

目錄

第 1 章：簡介

第 2 章：執行摘要

  • 關鍵見解

第3章：研究方法

  • 二次研究
  • 初步研究
    • 假設表述：
    • 宏觀經濟因素分析：
    • 發育基數：
    • 數據三角測量：
    • 國家級資料：

第 4 章：北美基因分型市場格局

  • 概述
  • PEST分析
  • 全球市佔率分析
    • NGS 文庫製備主要參與者的全球市佔率（%）
    • 基因分型領導企業的全球市場佔有率（%）
    • 基因表現領域領導企業的全球市場佔有率（%）

第 5 章：北美基因分型市場 - 主要市場動態

  • 市場促進因素：
    • 用於診斷遺傳疾病和罕見疾病
    • 生物技術和製藥行業的技術進步和研發投資不斷增加
  • 市場限制
    • 設備成本高，專業技術人員短缺
  • 市場機會
    • 擴大應用範圍
  • 未來趨勢
    • 個人化醫療日益普及
  • 促進因素和限制因素的影響：

第 6 章：基因分型市場 - 北美分析

  • 2021 至 2031 年基因分型市場收入

第 7 章：北美基因分型市場分析 - 依產品類型

  • 儀器
  • 試劑和試劑盒
  • 生物資訊學
  • 基因分型服務

第 8 章：北美基因分型市場分析 - 按技術

  • 微陣列
  • 毛細管電泳
  • 定序
  • 聚合酶鍊式反應（PCR）
  • 基質輔助雷射解吸/MALDI-TOF
  • 其他技術

第 9 章：北美基因分型市場分析 - 按應用

  • 藥物基因組學
  • 診斷及個人化醫療
  • 動物遺傳學
  • 農業生物技術
  • 其他應用

第 10 章：北美基因分型市場分析 - 按最終用戶

  • 製藥和生物製藥公司
  • 診斷與研究實驗室
  • 學術機構
  • 其他最終用戶

第 11 章：北美基因分型市場 - 國家分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥

第 12 章：產業格局

  • 概述
  • 基因分型市場的成長策略
  • 有機成長策略
    • 概述
  • 無機成長策略
    • 概述

第 13 章：公司簡介

  • Hoffmann-La Roche Ltd
  • QIAGEN NV
  • Merck KGaA
  • Thermo Fisher Scientific Inc
  • BioTek Instruments, Inc.
  • TRIMGEN CORPORATION
  • Illumina Inc
  • Danaher Corp
  • Bio-Rad Laboratories Inc
  • GE HealthCare Technologies Inc
  • Standard BioTools Inc
  • Laboratory Corp of America Holdings
  • Beckman Coulter Inc
  • BGI
  • Takara Bio Inc
  • DiaSorin SpA

第 14 章：附錄

Product Code: BMIRE00025971

The North America genotyping market was valued at US$ 12,044.57 million in 2023 and is expected to reach US$ 62,900.63 million by 2031; it is estimated to record a CAGR of 23.0% from 2023 to 2031.

Use in Diagnosis of Genetic and Rare Diseases Fuels North America Genotyping Market

According to the World Health Organization (WHO), ~35 million new cancer cases are likely to occur in 2050, a 77% increase from the corresponding 20 million cases in 2022. In 2022, the Alzheimer's Association stated that the number of people living with Alzheimer's in the US is rapidly increasing. The disease affects more than 6 million Americans from all age groups. As per the association's estimates, 6.5 million Americans aged more than 65 suffered from Alzheimer's as of 2022, and 73% of this population was aged 75 or older. As per a study published in the Journal of Health Monitoring, up to 300 million people worldwide suffer from rare diseases. Although individual diseases are rare, they collectively pose significant challenges to the global healthcare system.

Since cancer, Alzheimer's disease, and rare diseases are difficult to identify clinically, genotyping stands as the backbone of diagnostic testing in the population. DNA sequences obtained from genotyping can be compared to sample or reference sequences to determine variations. Genotyping is also employed to detect single-nucleotide polymorphisms (SNPs), which are minor variations in genetic complement within the population. The human genome has nearly 660 million SNPs, which makes them the most widespread genetic variation. Moreover, by comparing polymorphisms in healthy and diseased populations, genome-wide association studies (GWAS) can uncover links between common illnesses and SNPs. GWAS can untangle the molecular mechanisms in underlying disease states by finding probable causes. SNPs are even present in single-celled organisms, such as bacteria. SNP genotyping can discriminate between microorganism isolates and could even be accustomed to identifying antibiotic-resistant strains. SNP-based strain detection has a significant impact on each pharmaceutical and clinical analysis, and it has also been used in infectious disease epidemiology.

North America Genotyping Market Overview

The North America genotyping market is segmented into the US, Canada, and Mexico. Increasing adoption of technologically advanced products and solutions, and surging research and development activities are the factors benefiting the genotyping market in this region. Moreover, government-led programs such as the "All of Us Research Program," initiatives by various genomic communities, and the increasing awareness of genotyping services are the key drivers of the market expansion across North America.

North America Genotyping Market Revenue and Forecast to 2031 (US$ Million)

North America Genotyping Market Segmentation

The North America genotyping market is categorized into product type, technology, application, end user, and country.

Based on product type, the North America genotyping market is segmented into instruments, reagents and kits, bioinformatics, and genotyping services. The reagents and kits segment held the largest market share in 2023.

By technology, the North America genotyping market is categorized into microarrays, capillary electrophoresis, sequencing, polymerase chain reaction (PCR), matrix-assisted laser desorption / MALDI-TOF, and other technologies. The polymerase chain reaction (PCR) segment held the largest market share in 2023.

Based on application, the North America genotyping market is segmented into pharmacogenomics, diagnostics and personalized medicine, animal genetics, agricultural biotechnology, and other applications. The diagnostics and personalized medicine segment held the largest market share in 2023.

In terms of end user, the North America genotyping market is bifurcated into pharmaceutical and biopharmaceutical companies, diagnostic and research laboratories, academic institutes, and other end users. The pharmaceutical and biopharmaceutical companies segment held the largest market share in 2023.

By country, the North America genotyping market is segmented into the US, Canada, and Mexico. The US dominated the North America genotyping market share in 2023.

Hoffmann-La Roche Ltd, QIAGEN NV, Merck KGaA, Thermo Fisher Scientific Inc, BioTek Instruments, Inc, TRIMGEN CORPORATION, Illumina Inc, Danaher Corp, Bio-Rad Laboratories Inc, GE HealthCare Technologies Inc, Standard BioTools Inc, Laboratory Corp of America Holdings, Beckman Coulter Inc, BGI, Takara Bio Inc, and DiaSorin SpA. are some of the leading companies operating in the North America genotyping market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. North America Genotyping Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Global Market Share Analysis
    • 4.3.1 Global Market Share (%) of Leading Players for NGS Library Preparation
    • 4.3.2 Global Market Share (%) of Leading Player for Genotyping
    • 4.3.3 Global Market Share (%) of Leading Player for Gene Expression

5. North America Genotyping Market - Key Market Dynamics

  • 5.1 Market Drivers:
    • 5.1.1 Use in Diagnosis of Genetic and Rare Diseases
    • 5.1.2 Technological Advancements and Rising R&D Investments in Biotechnology and Pharmaceutical Industry
  • 5.2 Market Restraints
    • 5.2.1 High Cost of Equipment and Shortage of Skilled Professionals
  • 5.3 Market Opportunities
    • 5.3.1 Expanding Range of Applications
  • 5.4 Future Trends
    • 5.4.1 Increasing Popularity of Personalized Medicine
  • 5.5 Impact of Drivers and Restraints:

6. Genotyping Market - North America Analysis

  • 6.1 Genotyping Market Revenue (US$ Million), 2021-2031

7. North America Genotyping Market Analysis - by Product Type

  • 7.1 Instruments
    • 7.1.1 Overview
    • 7.1.2 Instruments: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Reagents and Kits
    • 7.2.1 Overview
    • 7.2.2 Reagents and Kits: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Bioinformatics
    • 7.3.1 Overview
    • 7.3.2 Bioinformatics: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Genotyping Services
    • 7.4.1 Overview
    • 7.4.2 Genotyping Services: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)

8. North America Genotyping Market Analysis - by Technology

  • 8.1 Microarray
    • 8.1.1 Overview
    • 8.1.2 Microarray: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Capillary Electrophoresis
    • 8.2.1 Overview
    • 8.2.2 Capillary Electrophoresis: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Sequencing
    • 8.3.1 Overview
    • 8.3.2 Sequencing: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Polymerase Chain Reaction (PCR)
    • 8.4.1 Overview
    • 8.4.2 Polymerase Chain Reaction (PCR): Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.5 Matrix-Assisted Laser Desorption / MALDI-TOF
    • 8.5.1 Overview
    • 8.5.2 Matrix-Assisted Laser Desorption / MALDI-TOF: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.6 Other Technologies
    • 8.6.1 Overview
    • 8.6.2 Other Technologies: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)

9. North America Genotyping Market Analysis - by Application

  • 9.1 Pharmacogenomics
    • 9.1.1 Overview
    • 9.1.2 Pharmacogenomics: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Diagnostics and Personalized Medicine
    • 9.2.1 Overview
    • 9.2.2 Diagnostics and Personalized Medicine: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.3 Animal Genetics
    • 9.3.1 Overview
    • 9.3.2 Animal Genetics: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.4 Agricultural Biotechnology
    • 9.4.1 Overview
    • 9.4.2 Agricultural Biotechnology: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.5 Other Applications
    • 9.5.1 Overview
    • 9.5.2 Other Applications: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)

10. North America Genotyping Market Analysis - by End-user

  • 10.1 Pharmaceutical and Biopharmaceutical Companies
    • 10.1.1 Overview
    • 10.1.2 Pharmaceutical and Biopharmaceutical Companies: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.2 Diagnostic and Research Laboratories
    • 10.2.1 Overview
    • 10.2.2 Diagnostic and Research Laboratories: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.3 Academic Institutes
    • 10.3.1 Overview
    • 10.3.2 Academic Institutes: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.4 Other End Users
    • 10.4.1 Overview
    • 10.4.2 Other End Users: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)

11. North America Genotyping Market - Country Analysis

  • 11.1 North America
    • 11.1.1 North America: Genotyping Market - Revenue and Forecast Analysis - by Country
      • 11.1.1.1 United States: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.1.1.1 United States: Genotyping Market Breakdown, by Product Type
        • 11.1.1.1.2 United States: Genotyping Market Breakdown, by Technology
        • 11.1.1.1.3 United States: Genotyping Market Breakdown, by Application
        • 11.1.1.1.4 United States: Genotyping Market Breakdown, by End-user
      • 11.1.1.2 Canada: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.1.2.1 Canada: Genotyping Market Breakdown, by Product Type
        • 11.1.1.2.2 Canada: Genotyping Market Breakdown, by Technology
        • 11.1.1.2.3 Canada: Genotyping Market Breakdown, by Application
        • 11.1.1.2.4 Canada: Genotyping Market Breakdown, by End-user
      • 11.1.1.3 Mexico: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.1.3.1 Mexico: Genotyping Market Breakdown, by Product Type
        • 11.1.1.3.2 Mexico: Genotyping Market Breakdown, by Technology
        • 11.1.1.3.3 Mexico: Genotyping Market Breakdown, by Application
        • 11.1.1.3.4 Mexico: Genotyping Market Breakdown, by End-user

12. Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies in Genotyping Market
  • 12.3 Organic Growth Strategies
    • 12.3.1 Overview
  • 12.4 Inorganic Growth Strategies
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 Hoffmann-La Roche Ltd
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 QIAGEN NV
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Merck KGaA
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Thermo Fisher Scientific Inc
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 BioTek Instruments, Inc.
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 TRIMGEN CORPORATION
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Illumina Inc
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Danaher Corp
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 Bio-Rad Laboratories Inc
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 GE HealthCare Technologies Inc
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments
  • 13.11 Standard BioTools Inc
    • 13.11.1 Key Facts
    • 13.11.2 Business Description
    • 13.11.3 Products and Services
    • 13.11.4 Financial Overview
    • 13.11.5 SWOT Analysis
    • 13.11.6 Key Developments
  • 13.12 Laboratory Corp of America Holdings
    • 13.12.1 Key Facts
    • 13.12.2 Business Description
    • 13.12.3 Products and Services
    • 13.12.4 Financial Overview
    • 13.12.5 SWOT Analysis
    • 13.12.6 Key Developments
  • 13.13 Beckman Coulter Inc
    • 13.13.1 Key Facts
    • 13.13.2 Business Description
    • 13.13.3 Products and Services
    • 13.13.4 Financial Overview
    • 13.13.5 SWOT Analysis
    • 13.13.6 Key Developments
  • 13.14 BGI
    • 13.14.1 Key Facts
    • 13.14.2 Business Description
    • 13.14.3 Products and Services
    • 13.14.4 Financial Overview
    • 13.14.5 SWOT Analysis
    • 13.14.6 Key Developments
  • 13.15 Takara Bio Inc
    • 13.15.1 Key Facts
    • 13.15.2 Business Description
    • 13.15.3 Products and Services
    • 13.15.4 Financial Overview
    • 13.15.5 SWOT Analysis
    • 13.15.6 Key Developments
  • 13.16 DiaSorin SpA
    • 13.16.1 Key Facts
    • 13.16.2 Business Description
    • 13.16.3 Products and Services
    • 13.16.4 Financial Overview
    • 13.16.5 SWOT Analysis
    • 13.16.6 Key Developments

14. Appendix

  • 14.1 About Us
  • 14.2 Glossary of Terms

List Of Tables

  • Table 1. North America Genotyping Market Segmentation
  • Table 2. Genotyping Market - Revenue and Forecast to 2031 (US$ Million) - by Product Type
  • Table 3. Genotyping Market - Revenue and Forecast to 2031 (US$ Million) - by Technology
  • Table 4. Genotyping Market - Revenue and Forecast to 2031 (US$ Million) - by Application
  • Table 5. Genotyping Market - Revenue and Forecast to 2031 (US$ Million) - by End-user
  • Table 6. United States: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Product Type
  • Table 7. United States: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 8. United States: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 9. United States: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by End-user
  • Table 10. Canada: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Product Type
  • Table 11. Canada: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 12. Canada: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 13. Canada: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by End-user
  • Table 14. Mexico: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Product Type
  • Table 15. Mexico: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 16. Mexico: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 17. Mexico: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by End-user
  • Table 18. Recent Organic Growth Strategies in Genotyping Market
  • Table 19. Recent Inorganic Growth Strategies in the Genotyping Market
  • Table 20. Glossary of Terms, Genotyping Market

List Of Figures

  • Figure 1. North America Genotyping Market Segmentation, by Country
  • Figure 2. PEST Analysis
  • Figure 3. Genotyping Market - Key Market Dynamics
  • Figure 4. Impact Analysis of Drivers and Restraints
  • Figure 5. Genotyping Market Revenue (US$ Million), 2021-2031
  • Figure 6. Genotyping Market Share (%) - by Product Type (2023 and 2031)
  • Figure 7. Instruments: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Reagents and Kits: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Bioinformatics: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Genotyping Services: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Genotyping Market Share (%) - by Technology (2023 and 2031)
  • Figure 12. Microarray: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Capillary Electrophoresis: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Sequencing: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Polymerase Chain Reaction (PCR): Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Matrix-Assisted Laser Desorption / MALDI-TOF: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Other Technologies: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Genotyping Market Share (%) - by Application (2023 and 2031)
  • Figure 19. Pharmacogenomics: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 20. Diagnostics and Personalized Medicine: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. Animal Genetics: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Agricultural Biotechnology: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. Other Applications: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 24. Genotyping Market Share (%) - by End-user (2023 and 2031)
  • Figure 25. Pharmaceutical and Biopharmaceutical Companies: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 26. Diagnostic and Research Laboratories: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 27. Academic Institutes: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 28. Other End Users: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 29. North America Genotyping Market, by Key Countries - Revenue (2023) (US$ Million)
  • Figure 30. North America: Genotyping Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 31. United States: Genotyping Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 32. Canada: Genotyping Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 33. Mexico: Genotyping Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 34. Growth Strategies in Genotyping Market